Fig. 1

Association of CCL5/IFNG-CXCL9/10 axis, TI-NK cell signature and response to neoadjuvant treatment with anti-HER2 antibodies. A Images showing CD56 staining by IHC of representative tumors included in the array. Arrows point to CD56 + lymphocytes. ER: Estrogen Receptor. B TIL score, TI-NK cell number and tumor area in the analysed tumor biopsies (n = 12). C Biological pathways enriched in TI-NK cell infiltrated tumors. Dashed line corresponds to -log (p value) = 1.3. D Relative expression of CCL5, IFNG, CXCL9 and CXCL10 genes in all tumors included in the array. E Pearsons’ correlation coefficient between indicated genes. F Pearsons’ correlation coefficient between indicated genes, TI-NK cell numbers and TIL scores in the corresponding biopsies. Asterisks indicate statistical significance (**** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.05). G-I A gene signature predicting NK cell infiltration (see methods), IFNG, GZMB, CCL5, CXCL9 and CXCL10 gene expression levels were analysed in treatment naïve HER2-positive breast tumors from the Phase II Trial dataset (GSE130786). G Pearson correlation coefficient between indicated genes. Asterisk label significant correlations. H Correlation between IFNG expression levels and TI-NK cell score. I Odds Ratio (OR) and 97.5 confidence interval (CI) of TI-NK cell (NKsig), IFNG, GZMB, CCL5, CXCL9 and CXCL10 scores for pCR to trastuzumab. Asterisk label significant genes